Vincent travels to the University of Vermont to speak with Jason, Emily, Jessica, and Dimitry about their careers and their work on SARS-CoV-2, hantaviruses, poliovirus, influenza virus, and the involvement of viruses in the autoimmune disease multiple sclerosis.
In his weekly clinical update, Dr. Griffin discusses high Influenza incidence and disease severity among children and adolescents aged <18 years, neurologic effects of SARS-CoV-2 transmitted among dogs, effectiveness of monovalent mRNA vaccines against Omicron XBB infection in Singaporean children younger than 5 years, the effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions, incidence and impact of acute pericarditis in hospitalized patients with COVID‐19, serotonin reduction in post-acute sequelae of viral infection, prevalence and risk factors for long COVID and post-COVID-19 condition in Africa, safety profile and clinical and virological outcomes of nirmatrelvir-ritonavir treatment in patients with advanced chronic kidney disease and COVID-19, antiviral efficacy of molnupiravir vs ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19.
From the Centers for Excellence in Influenza Research and Response meeting in Baltimore, Vincent speaks with Ron Fouchier, Rafael Medina, and Louse Moncla about recent changes in the epidemiology of avian H5N1 influenza virus and the threat to humans and other animals.
In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to covid-19 complications, antibiotic use among hospitalized patients with COVID-19 in the United States, one week of oral Camostat vs Placebo in nonhospitalized adults with mild-to-moderate COVID-19, assessment of the available therapeutic approaches for severe COVID-19, optimal duration of systemic Corticosteroids in COVID-19 treatment, effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients, and the safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic Kidney disease and COVID-19.
TWiV reviews the 2023 Nobel Prize in Physiology or Medicine awarded to Katalin Karikó and Drew Weissman for their identification nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19, and accelerated mutation of SARS-CoV-2 in white-tailed deer.
In his weekly clinical update, Dr. Griffin discusses the effectiveness of maternal mRNA COVID-19 vaccination during pregnancy against COVID-19–associated hospitalizations in infants aged <6 months during SARS-CoV-2 Omicron predominance, COVID-19 vaccination recommendations and practices for women of reproductive age by health care providers, molnupiravir for intra-household prevention of COVID-19, delayed peak SARS-CoV-2 viral loads relative to symptom onset and implications for COVID-19 testing programs, viral kinetics of sequential SARS-CoV-2 infections, FDA authorizes updated Novavax COVID-19 vaccine formulated to better protect against currently circulating variants, antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, long-term cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors, SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels, and the efficacy of gabapentin For post-COVID-19 olfactory dysfunction.
TWiV explains how immune profiling was used to identify distinguishing features of Long COVID, and how a co-opted feline endogenous retroviral envelope promotes cell survival by controlling copper transport and homeostasis in cats.
In his weekly clinical update, Dr. Griffin discusses a molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, inhaled fluticasone furoate for outpatient treatment of COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, early antibody treatment, inflammation, and risk of post-COVID conditions, autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability, and multiorgan MRI findings after hospitalization with COVID-19 in the UK.
TWiV explains a study of postacute sequelae of COVID-19 at 2 years, and airborne transmission of human-isolated avian H3N8 influenza virus between ferrets.
In his weekly clinical update, Dr. Griffin discusses wastewater surveillance data as a complement to emergency department visit data for tracking the incidence of influenza A and RSV, chatbot-delivered online intervention to promote seasonal Influenza vaccination during the COVID-19 pandemic, temporal assessment of disparities in California COVID-19 mortality by industry, modeling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City, can high COVID-19 vaccination rates in adults help protect unvaccinated children, Nirmatrelvir/Ritonavir use and hospitalizations or death in previously uninfected non-hospitalized high-risk population with COVID-19, Optimal duration of systemic corticosteroids in COVID-19 treatment, and vaccination after developing long COVID.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.